Ontology-Based Vaccine and Drug Adverse Event Representation and Theory-Guided Systematic Causal Network Analysis Toward Integrative Pharmacovigilance Research

Current Pharmacology Reports

Volumn 2, Issue 3, 2016, Pages 113-128

  He, Yongqun ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adverse event; Bioinformatics; Drug; Ontology of Adverse Events (OAE); Ontology of Drug Neuropathy Adverse Events (ODNAE); Ontology of Vaccine Adverse Events (OVAE); Pharmacovigilance; The Immune Response Gene Network Theory; The OneNet Theory of Life; Vaccine

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); INTERFERON REGULATORY FACTOR 1;

BIOINFORMATICS; DRUG SURVEILLANCE PROGRAM; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; GENE ONTOLOGY; GENETIC POLYMORPHISM; GENOTYPE; IMMUNE RESPONSE; IMMUNOGENETICS; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; MEDICAL TERMINOLOGY; ONTOLOGY OF DRUG NEUROPATHY ADVERSE EVENTS; ONTOLOGY OF VACCINE ADVERSE EVENTS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THYROIDITIS; VACCINATION;

EID: 84992427784     PISSN: None     EISSN: 2198641X     Source Type: Journal    
DOI: 10.1007/s40495-016-0055-0     Document Type: Review

References (108)

1. Silvers LE, Ellenberg SS, Wise RP, Varricchio FE, Mootrey GT, Salive ME. The epidemiology of fatalities reported to the vaccine adverse event reporting system 1990–1997. Pharmacoepidemiol Drug Saf. 2001;10(4):279–85.
2. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)--United States, 1991–2001. MMWR Surveill Summ. 2003;52(1):1–24.
3. Sarntivijai S, Xiang Z, Shedden KA, Markel H, Omenn GS, Athey BD, et al. Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines. PLoS One. 2012;7(11):e49941.
4. Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, et al. Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013;381(9876):1461–8.
5. Why Learn about Adverse Drug Reactions (ADR)? [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm114848.htm]
6. Qing-ping S, Xiao-dong J, Feng D, Yan L, Mei-ling Y, Jin-xiu Z, et al. Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China. BMC Health Serv Res. 2014;14:73.
7. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama. 1998;279(15):1200–5.
8. FDA Adverse Event Reporting System (FAERS) [FDA Adverse Event Reporting System (FAERS): http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm, accessed on May 22 2015.]
9. Chen RT, Rastogi SC, Mullen JR, Hayes SW, Cochi SL, Donlon JA, et al. The vaccine adverse event reporting system (VAERS). Vaccine. 1994;12(6):542–50.
10. Varricchio F, Iskander J, Destefano F, Ball R, Pless R, Braun MM, et al. Understanding vaccine safety information from the vaccine adverse event reporting system. Pediatr Infect Dis J. 2004;23(4):287–94.
11. He Y, Toldo L, Burns G, Tao C, Abernethy DR. A 2012 workshop: vaccine and drug ontology in the study of mechanism and effect (VDOSME 2012). J Biomed Semant. 2012;3(1):12.
12. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109–17.
13. Introductory Guide MedDRA Version 18.0 [http://www.meddra.org/sites/default/files/guidance/file/intguide_18_0_english.pdf]
14. The Common Terminology Criteria for Adverse Events (CTCAE) [http://evs.nci.nih.gov/ftp1/CTCAE/About.html, access on October 7, 2015]
15. The WHO Adverse Reaction Terminology – WHO-ART [https://www.umc-products.com/graphics/28010.pdf]
16. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25–9.
17. Brinkman RR, Courtot M, Derom D, Fostel JM, He Y, Lord P, et al. Modeling biomedical experimental processes with OBI. J Biomed Semant. 2010;1(1):S7.
18. Zheng J, Manduchi E, Stoeckert Jr CJ. Development of an application Ontology for beta cell genomics based on the Ontology for biomedical investigations. In: The 4th International Conference on Biomedical Ontology (ICBO-2013): July 7–12 2013. Montreal, Qc, Canada: CEUR Workshop Proceedings; 2013. p. 62–7.
19. Brinkman RR, Courtot M, Derom D, Fostel J, He Y, Lord P, et al. Modeling biomedical experimental processes with OBI. J Biomed Semant. 2010;21(21):S27. doi:10.1186/2041-1480-1181-S1181-S1187.
20. Dugan VG, Emrich SJ, Giraldo-Calderon GI, Harb OS, Newman RM, Pickett BE, et al. Standardized metadata for human pathogen/vector genomic sequences. PLoS One. 2014;9(6), e99979.
21. Sarntivijai S, Lin Y, Xiang Z, Meehan TF, Diehl AD, Vempati UD, et al. CLO: The Cell Line Ontology. J Biomed Semant. 2014;5:37.
22. He Y, Cowell L, Diehl AD, Mobley HL, Peters B, Ruttenberg A, et al. VO: Vaccine Ontology. In: The 1st International Conference on Biomedical Ontology (ICBO-2009): July 24–26 2009. Buffalo, NY, USA: Nature Precedings; 2009.
23. Ozgur A, Xiang Z, Radev DR, He Y. Mining of vaccine-associated IFN-gamma gene interaction networks using the Vaccine Ontology. J Biomed Semant. 2011;2(2):S8.
24. Lin Y, He Y. Ontology representation and analysis of vaccine formulation and administration and their effects on vaccine immune responses. J Biomed Semant. 2012;3(1):17.
25. Yang B, Sayers S, Xiang Z, He Y. Protegen: a web-based protective antigen database and analysis system. Nucleic Acids Res. 2011;39(Database issue):D1073–1078.
26. Sayers S, Ulysse G, Xiang Z, He Y. Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development. J Biomed Biotechnol. 2012;2012:831486.
27. Racz R, Chung M, Xiang Z, He Y. Systematic annotation and analysis of “virmugens”—virulence factors whose mutants can be used as live attenuated vaccines. Vaccine. 2013;31(5):797–805.
28. He Y, Racz R, Sayers S, Lin Y, Todd TE, Hur J, et al. Updates on the Web-based VIOLIN Vaccine Database and Analysis System. Nucl Acids Res. 2013. doi:10.1093/nar/gkt1133. (Database Issue):1–9.
29. Hur J, Xiang Z, Feldman EL, He Y. Ontology-based Brucella vaccine literature indexing and systematic analysis of gene-vaccine association network. BMC Immunol. 2011;12:49.
30. Hanna J, Joseph E, Brochhausen M, Hogan WR. Building a drug ontology based on RxNorm and other sources. J Biomed Semant. 2013;4(1):44.
31. He Y, Sarntivijai S, Lin Y, Xiang Z, Guo A, Zhang S, et al. OAE: The Ontology of Adverse Events. J Biomed Semant. 2014;5:29.
32. Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther. 2007;82(6):653–64.
33. Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics. 2009;10(5):837–52.
34. He Y. Ontology-supported research on vaccine efficacy, safety and integrative biological networks. Expert Rev Vaccines. 2014;13(7):825–41.
35. Deans AR, Lewis SE, Huala E, Anzaldo SS, Ashburner M, Balhoff JP, et al. Finding our way through phenotypes. PLoS Biol. 2015;13(1), e1002033.
36. Berners-Lee T, Hendler J, Lassila O. The Semantic Web. Sci Am 2001;29–37.
37. Schroll JB, Maund E, Gotzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. PLoS One. 2012;7(7):e41174.
38. The Uppsala Monitoring Centre: The WHO Adverse Reaction Terminology – WHO-ART, Terminology for coding clinical information in relation to drug therapy. In.; 2015: http://www.umc-products.com/graphics/28010.pdf.
39. Brown SH, Elkin PL, Bauer BA, Wahner-Roedler D, Husser CS, et al. SNOMED CT: utility for a general medical evaluation template. AMIA Annl Symp Proc/AMIA Symp AMIA Symp. 2006; 101–105.
40. Mullooly JP, Donahue JG, DeStefano F, Baggs J, Eriksen E, Group VSDDQW. Predictive value of ICD-9-CM codes used in vaccine safety research. Methods Inf Med. 2008;47(4):328–35.
41. Iavindrasana J, Bousquet C, Degoulet P, Jaulent MC. Clustering WHO-ART terms using semantic distance and machine learning algorithms. AMIA Annu Symp Proc/AMIA Symp AMIA Symp. 2006; 369–373.
42. Brown EG. Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART. Drug Saf. 2002;25(6):445–52.
43. Declerck G, Hussain S, Daniel C, Yuksel M, Laleci GB, Twagirumukiza M, et al. Bridging data models and terminologies to support adverse drug event reporting using EHR data. Methods Inf Med. 2015;54(1):24–31.
44. Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012;45(4):689–96.
45. Nadkarni PM, Darer JD. Determining correspondences between high-frequency MedDRA concepts and SNOMED: a case study. BMC Med Inform Decis Making. 2010;10:66.
46. Bodenreider O. Using SNOMED CT in combination with MedDRA for reporting signal detection and adverse drug reactions reporting. AMIA Annu Symp Proc/AMIA Symp AMIA Symp. 2009;2009:45–9.
47. Van Rees R. Clarity in the usage of the terms ontology, taxonomy and classification. CIB Report. 2003;284(432):1–8.
48. Ceusters W, Smith B, Flanagan J. Ontology and medical terminology: why description logics are not enough. In: Towards an Electronic Patient Record (TEPR 2003): 2003; Boston, MA.
49. Zhichkin PE, Athey BD, Avigan MI, Abernethy DR. Needs for an expanded ontology-based classification of adverse drug reactions and related mechanisms. Clin Pharmacol Ther. 2012;91(6):963–5.
50. Schulz S, Balkanyi L, Cornet R, Bodenreider O. From concept representations to ontologies: a paradigm shift in health informatics? Healthc Inform Res. 2013;19(4):235–42.
51. Tirmizi SH, Aitken S, Moreira DA, Mungall C, Sequeda J, Shah NH, et al. Mapping between the OBO and OWL ontology languages. J Biomed Semant. 2011;2(1):S3.
52. W3C: OWL 2 Web Ontology Language document overview. 2009: http://www.w3.org/TR/2009/REC-owl2002-overview-20091027/. Accessed on March 20091021, 20092014.
53. Smith B, Ashburner M, Rosse C, Bard J, Bug W, Ceusters W, et al. The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nat Biotechnol. 2007;25(11):1251–5.
54. Grenon P, Smith B. SNAP and SPAN: towards dynamic spatial Ontology. Spat Cogn Comput. 2004;4(1):69–103.
55. The Ontology for General Medical Science (OGMS) [https://code.google.com/p/ogms/]
56. Xiang Z, Mungall C, Ruttenberg A, He Y. Ontobee: a linked data server and browser for ontology terms. In: The 2nd International Conference on Biomedical Ontologies (ICBO): 2011. Buffalo, NY, USA: CEUR Workshop Proceedings; 2013. p. 279–81.
57. Marcos E, Zhao B, He Y. The Ontology of Vaccine Adverse Events (OVAE) and its usage in representing and analyzing adverse events associated with US-licensed human vaccines. J Biomed Semant. 2013;4(1):40.
58. Xiang Z, Todd T, Ku KP, Kovacic BL, Larson CB, Chen F, et al. VIOLIN: vaccine investigation and online information network. Nucleic Acids Res. 2008;36(Database issue):D923–928.
59. He Y, Racz R, Sayers S, Lin Y, Todd T, Hur J, et al. Updates on the web-based VIOLIN vaccine database and analysis system. Nucleic Acids Res. 2014;42(1):D1124–1132.
60. He Y, Rappuoli R, De Groot AS, Chen RT. Emerging vaccine informatics. J Biomed Biotechnol. 2010;2010:218590.
61. Hur J, Ozgur A, Xiang Z, He Y. Identification of fever and vaccine-associated gene interaction networks using ontology-based literature mining. J Biomed Semant. 2012;3(1):18.
62. Zhang Y, Tao C, He Y, Kanjamala P, Liu H. Network-based analysis of vaccine-related associations reveals consistent knowledge with the vaccine ontology. J Biomed Semant. 2013;4(1):33.
63. Guo A, Racz R, Hur J, Lin Y, Xiang Z, Zhao L, et al. Ontology-based collection, representation and analysis of drug-associated neuropathy adverse events In: The 4th International Workshop on Vaccine and Drug Ontology Studies (VDOS-2015), in conjunction with the International Conference on Biomedical Ontologies (ICBO-2015): July 27–30 2015; Lisbon, Portugal; 2015. p1–6.
64. Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. J Ame Med Inform Assoc: JAMIA. 2011;18(4):441–8.
65. Carter JS, Brown SH, Bauer BA, Elkin PL, Erlbaum MS, Froehling DA, et al. Categorical information in pharmaceutical terminologies. AMIA Annu Symp Proc/AMIA Symp AMIA Symp. 2006; 116–120.
66. Hastings J, de Matos P, Dekker A, Ennis M, Harsha B, Kale N, et al. The ChEBI reference database and ontology for biologically relevant chemistry: enhancements for 2013. Nucleic Acids Res. 2013;41(Database issue):D456–463.
67. Stanley Jr SL, Frey SE, Taillon-Miller P, Guo J, Miller RD, Koboldt DC, et al. The immunogenetics of smallpox vaccination. J Infect Dis. 2007;196(2):212–9.
68. Reif DM, McKinney BA, Motsinger AA, Chanock SJ, Edwards KM, Rock MT, et al. Genetic basis for adverse events after smallpox vaccination. J Infect Dis. 2008;198(1):16–22.
69. Pulendran B, Miller J, Querec TD, Akondy R, Moseley N, Laur O, et al. Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis. 2008;198(4):500–7.
70. Lin Y, He Y. The ontology of genetic susceptibility factors (OGSF) and its application in modeling genetic susceptibility to vaccine adverse events. J Biomed Semant. 2014;5:19.
71. Poland GA, Ovsyannikova IG, Kennedy RB, Haralambieva IH, Jacobson RM. Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. OMICS. 2011;15(9):625–36.
72. Poland GA, Kennedy RB, McKinney BA, Ovsyannikova IG, Lambert ND, Jacobson RM, et al. Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century. Semin Immunol. 2013;25(2):89–103.
73. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000;3(5):445–50.
74. Futuyma DJ. Evolutionary Biology, 3rd edn: Sinauer Associates; 1997.
75. Mazzarello P. A unifying concept: the history of cell theory. Nat Cell Biol. 1999;1(1):E13–15.
76. Perelson AS. Immune network theory. Immunol Rev. 1989;110:5–36.
77. Griffiths JF, Miller JH, Suzuki DT, Lewontin RC, Gelbart WM. An Introduction to Genetic Analysis. 7th ed. New York: W. W. Freeman and Company; 2000.
78. Effectiveness [https://en.wikipedia.org/wiki/Effectiveness]
79. Flay BR. Efficacy and effectiveness trials (and other phases of research) in the development of health promotion programs. Prev Med. 1986;15(5):451–74.
80. Wells JD. Effective theories in physics: from planetary orbits to elementary particle masses: SpringerBriefs in Physics. 2012.
81. Costa PCG, Laskey KB, Blasch E, Jousselme A-L. Towards unbiased evaluation of uncertainty reasoning: The URREF ontology. In: The 15th International Conference on Information Fusion: 9–12 July Singapore; 2012.2301–2308.
82. Heather N. The efficacy-effectiveness distinction in trials of alcohol brief intervention. Addict Sci Clin Pract. 2014;9:13.
83. Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis. 2010;201(11):1607–10.
84. Boccaletti S, Latora V, Moreno Y, Chavez M, Hwang DU. Complex networks: structure and dynamics. Phys Rep. 2006;424:175–308.
85. HarshaRani GV, Vayttaden SJ, Bhalla US. Electronic data sources for kinetic models of cell signaling. J Biochem. 2005;137(6):653–7.
86. Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 2011;39(Database issue):D691–697.
87. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome. Nucleic Acids Res. 2004;32(Database issue):D277–280.
88. Latendresse M, Paley S, Karp PD. Browsing metabolic and regulatory networks with BioCyc. Methods Mol Biol. 2012;804:197–216.
89. BioCarta Apoptosis pathway [http://www.biocarta.com/genes/Apoptosis.asp]
90. Thorn CF, Klein TE, Altman RB. Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics. 2010;11(4):501–5.
91. Hur J, Ozgur A, Xiang Z, He Y. Development and application of an interaction network ontology for literature mining of vaccine-associated gene-gene interactions. J Biomed Semant. 2015;6:2.
92. He Y, Xiang Z. HINO: a BFO-aligned ontology representing human molecular interactions and pathways. arXiv. 2013; arXiv:1311.3355.
93. Buttigieg PL, Morrison N, Smith B, Mungall CJ, Lewis SE, Consortium E. The environment ontology: contextualising biological and biomedical entities. J Biomed Semant. 2013;4(1):43.
94. Malone J, Holloway E, Adamusiak T, Kapushesky M, Zheng J, Kolesnikov N, et al. Modeling sample variables with an experimental factor ontology. Bioinformatics. 2010;26(8):1112–8.
95. Tettelin H, Masignani V, Cieslewicz MJ, Donati C, Medini D, Ward NL, et al. Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial “pan-genome”. Proc Natl Acad Sci U S A. 2005;102(39):13950–5.
96. Medini D, Donati C, Tettelin H, Masignani V, Rappuoli R. The microbial pan-genome. Curr Opin Genet Dev. 2005;15(6):589–94.
97. Li R, Li Y, Zheng H, Luo R, Zhu H, Li Q, et al. Building the sequence map of the human pan-genome. Nat Biotechnol. 2010;28(1):57–63.
98. Sanchez C, Lachaize C, Janody F, Bellon B, Roder L, Euzenat J, et al. Grasping at molecular interactions and genetic networks in Drosophila melanogaster using FlyNets, an Internet database. Nucleic Acids Res. 1999;27(1):89–94.
99. Bonetta L. Protein-protein interactions: interactome under construction. Nature. 2010;468(7325):851–4.
100. Bouveret E, Brun C. Bacterial interactomes: from interactions to networks. Methods Mol Biol. 2012;804:15–33.
101. Watts DJ, Strogatz SH. Collective dynamics of 'small-world' networks. Nature. 1998;393(6684):440–2.
102. Arenas A, Diaz-Guilera A, Kurths J, Moreno Y, Zhou C. Synchronization in complex networks. Phys Rep. 2008;469:93–153.
103. The protege ontology editor [http://protege.stanford.edu/]
104. Whetzel PL, Noy NF, Shah NH, Alexander PR, Nyulas C, Tudorache T, et al. BioPortal: enhanced functionality via new Web services from the National Center for Biomedical Ontology to access and use ontologies in software applications. Nucleic Acids Res. 2011;39:W541–545.
105. Xiang Z, Courtot M, Brinkman RR, Ruttenberg A, He Y. OntoFox: web-based support for ontology reuse. BMC Res Notes. 2010;3(175):1–12.
106. Zheng J, Xiang Z, Stoeckert Jr CJ, He Y. Ontodog: a web-based ontology community view generation tool. Bioinformatics. 2014;30(9):1340–2.
107. Xiang Z, Zheng J, Lin Y, He Y. Ontorat: automatic generation of new ontology terms, an-notations, and axioms based on ontology design patterns. J Biomed Semant. 2015;6(1):4–10.
108. Xiang Z, He Y. IDO extensions alignment using Ontobeep. In: Infectious Disease Ontology (IDO) Workshop 2010: December 8–9; Baltimore, MD, USA. 2010.